# Lexicon Pharmaceuticals clinical trials: 61 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 61 trials with Lexicon Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Lexicon Pharmaceuticals: 61 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/lexicon-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 61
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 61, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 1, 2024 | NCT06481891 | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Lexicon Pharmaceuticals | Phase 3 | Active not recruiting | Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06481891) |
| January 12, 2024 | NCT06203002 | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) | Lexicon Pharmaceuticals | Phase 2 | Completed | Diabetic Peripheral Neuropathic Pain | 496 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06203002) |
| December 10, 2020 | NCT04662281 | Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia | Lexicon Pharmaceuticals | Phase 2 | Completed | Postherpetic Neuralgia | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04662281) |
| July 2, 2020 | NCT04455633 | Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain | Lexicon Pharmaceuticals | Phase 2 | Completed | Diabetic Peripheral Neuropathy, Diabetes | 319 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04455633) |
| May 11, 2018 | NCT03521934 | Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) | Lexicon Pharmaceuticals | Phase 3 | Terminated | Heart Failure, Type 2 Diabetes Mellitus | 1,222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03521934) |
| February 6, 2018 | NCT03423446 | Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment | Lexicon Pharmaceuticals | Phase 1 | Completed | Hepatic Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03423446) |
| December 29, 2017 | NCT03386344 | Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate... | Lexicon Pharmaceuticals | Phase 3 | Terminated | Type 2 Diabetes Mellitus | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03386344) |
| November 22, 2017 | NCT03351478 | Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 2 Diabetes Mellitus | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03351478) |
| November 6, 2017 | NCT03332771 | Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 2 Diabetes Mellitus | 954 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03332771) |
| October 19, 2017 | NCT03315143 | Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at... | Lexicon Pharmaceuticals | Phase 3 | Terminated | Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases | 10,584 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03315143) |
| October 5, 2017 | NCT03302845 | A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects | Lexicon Pharmaceuticals | Phase 1 | Completed | Drug-drug Interaction | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03302845) |
| September 25, 2017 | NCT03292653 | Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure | Lexicon Pharmaceuticals | Phase 2 | Terminated | Cardiac Failure Aggravated | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03292653) |
| September 18, 2017 | NCT03285594 | Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 2 Diabetes Mellitus | 571 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03285594) |
| August 8, 2017 | NCT03242252 | Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3 | 787 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03242252) |
| August 8, 2017 | NCT03242018 | A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4 | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03242018) |
| February 28, 2017 | NCT03066830 | Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 2 Diabetes Mellitus | 507 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03066830) |
| October 6, 2016 | NCT02926950 | Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 2 Diabetes Mellitus | 518 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02926950) |
| October 6, 2016 | NCT02926937 | Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 2 Diabetes Mellitus | 399 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02926937) |
| January 6, 2016 | NCT02647918 | Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function | Lexicon Pharmaceuticals | Phase 1 | Completed | Renal Impairment, Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02647918) |
| August 21, 2015 | NCT02531035 | A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood | 1,405 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02531035) |
| July 10, 2015 | NCT02494609 | Oral Contraceptive DDI Study | Lexicon Pharmaceuticals | Phase 1 | Unknown | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02494609) |
| June 15, 2015 | NCT02471274 | PK Study of Sotagliflozin in Subjects With Hepatic Impairment | Lexicon Pharmaceuticals | Phase 1 | Completed | Hepatic Impairment, Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02471274) |
| June 2, 2015 | NCT02459899 | Dose-ranging Study in Patients With Type 1 Diabetes Mellitus | Lexicon Pharmaceuticals | Phase 2 | Completed | Type 1 Diabetes Mellitus | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02459899) |
| April 20, 2015 | NCT02421510 | Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 1 Diabetes Mellitus | 782 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02421510) |
| March 10, 2015 | NCT02384941 | Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have... | Lexicon Pharmaceuticals | Phase 3 | Completed | Type 1 Diabetes Mellitus | 793 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02384941) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 26 |
| Phase 1/2 | 1 |
| Phase 2 | 16 |
| Phase 3 | 18 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 55 |
| Terminated | 4 |
| Unknown | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 17 |
| Serotonin Syndrome | 6 |
| Diabetes Mellitus, Type 1 | 6 |
| Irritable Bowel Syndrome | 3 |
| Renal Insufficiency, Chronic | 3 |
| Arthritis, Rheumatoid | 3 |
| Heart Failure | 2 |
| Diabetes Mellitus | 2 |
| Renal Insufficiency | 2 |
| Memory Disorders | 1 |
| Cardiomyopathy, Hypertrophic | 1 |
| Neuralgia, Postherpetic | 1 |
| Glaucoma, Open-Angle | 1 |
| Ocular Hypertension | 1 |
| Colitis, Ulcerative | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Pediatric cardiology practices in the United States](https://specstream.ai/data/businesses/pediatric-cardiology-practices/united-states)
- [Dentistry schools in the United States](https://specstream.ai/data/businesses/dentistry-schools/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
- [Hepatology practices in the United States](https://specstream.ai/data/businesses/hepatology-practices/united-states)
- [Architectural design firms in the United States](https://specstream.ai/data/businesses/architectural-design-firms/united-states)
